- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Article
Provectus expands compassionate use for PV-10
Author(s):
National report - Provectus Pharmaceuticals has expanded its compassionate use program for PV-10, which is being developed as a therapeutic agent for metastatic melanoma and other cancers, making it available for select cancer patients in the United States, according to a press release.
National report
- Provectus Pharmaceuticals has expanded its compassionate use program for PV-10, which is being developed as a therapeutic agent for metastatic melanoma and other cancers, making it available for select cancer patients in the United States, according to a press release.
The program, being implemented under the U.S. Food and Drug Administration (FDA) guidelines covering compassionate use of an investigational new drug, began at St. Luke’s Hospital & Health Network in Bethlehem, Pa. Provectus recently announced that all patients in the phase 2 clinical trial for metastatic melanoma had been treated, according to the press release.
The program was initiated in Australia in June 2009. Both the U.S. program and the Australian program make PV-10 available only for cancer indications that do not involve visceral organs. Available indications include certain breast cancers, basal cell carcinoma, squamous cell carcinoma, certain head and neck cancers and melanoma.
Provectus plans to expand the compassionate use program to other U.S. sites in the coming months.
